BIG 2-98 TAX
BIG 2-98 TAX is an intergroup phase III trial to evaluate the activity of docetaxel, given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients.
The study found a statistically significant improvement in disease-free survival for sequential rather than combination anthracycline/taxane CT (ASCO 2006).
Coordinating group: BrEAST
Start date: June 1998
Closure date: June 2001
Target nr. of patients: 2730
Final accrual: 2887
ClinicalTrials.gov Identifier: NCT00174655